What changed in Zoetis Inc.'s latest annual report
In the year ended 31 Dec 2025, Zoetis Inc.'s revenue rose 2.3% to USD 9.47bn, from USD 9.26bn; net income rose 7.5% to USD 2.67bn, from USD 2.49bn; long-term debt rose 73.2% to USD 9.04bn, from USD 5.22bn.
Year ended 31 Dec 2025. Source: 10-K filed 12 Feb 2026, read it on SEC EDGAR.
USD 9.26bn to USD 9.47bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 9.26bn | 9.47bn | Up 2.3% |
| Net income | 2.49bn | 2.67bn | Up 7.5% |
| Total assets | 14.24bn | 15.47bn | Up 8.6% |
| Total liabilities | 9.47bn | 12.14bn | Up 28.2% |
| Long-term debt | 5.22bn | 9.04bn | Up 73.2% |
| Shareholders' equity | 4.77bn | 3.33bn | Down 30.2% |
Questions people ask
Did Zoetis Inc.'s revenue grow last year?
Revenue grew 2.3%, from USD 9.26bn to USD 9.47bn in the year ended 31 Dec 2025.
Is Zoetis Inc. profitable?
Yes. Net income was USD 2.67bn in the year ended 31 Dec 2025. The year before: USD 2.49bn.
How much cash and debt does Zoetis Inc. have?
At its latest year end (31 Dec 2025), Zoetis Inc. reported long-term debt of USD 9.04bn.
Where do these numbers come from?
From Zoetis Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Zoetis Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%